Cannabis Law Report

JUNE 19, 2022

Unlike novel chemical compounds that are synthetically produced in the pharmaceutical industry through drug development programs, psychedelic compounds have a long and established history. As we see more data emerge from clinical trials, we are likely to see patent applications covering stability, pharmacokinetic, and pharmacodynamic data.

Clinical Trials 52

Clinical Trials Microdosing Data Pharmaceutical 52

Cannabis Law Report

MARCH 3, 2022

The team at Microdose, the world’s biggest medical psychedelic conference , said the country’s move to permit Med Plant Science Ltd to produce psychedelic compounds makes it the first country to legalize all psychedelic medicine. . The eventual trials would target PTSD, addiction, alcoholism, depression, and anxiety. and Europe.

Research and Development 52

Research and Development Medicine Clinical Trials Microdosing 52

Cannabis Law Report

JULY 13, 2022

“Their position as therapeutic practitioners, as well as their work in conducting the kind of clinical trials necessary to advance regulatory outcomes for psychedelic medicines, make them ideal partners in alignment with Optimi’s strategic goals.”.

Therapy 52

Therapy Clinical Trials Microdosing Research and Development 52

Canna Law Blog

NOVEMBER 27, 2021

In fact, Small Pharma has been conducting trials as reported by the BBC and expanded its clinical trial this past summer. regulators to launch a clinical program to study the use of DMT for the treatment of stroke-related dysfunction. Compass Pathways Releases Phase 2B Trial Results.

Therapy 98

Therapy Clinical Trials DEA Microdosing 98

Cannabis Law Report

AUGUST 10, 2022

According to CAMH’s lead investigator, clinical trials suggest that psilocybin, combined with psychotherapy, can produce “ sustained antidepressant effects” in individuals living with severe depression.

Clinical Trials 52

Clinical Trials Research and Development Therapy Microdosing 52

Cannabis Law Report

JUNE 4, 2021

Rick, and MAPS, have published hundreds of research papers, articles, and reports over the past several decades in addition to participation in dozens of clinical trials and international studies. David joined the faculty at UC Davis in 2015, where he established a research program at the interface of chemistry and neuroscience.

Research and Development 51

Research and Development Medicine Treatment Pharmaceutical 51